2026-01-15 - Analysis Report
**Financial Report for Eli Lilly and Co (LLY)**

**Company Overview:** Eli Lilly and Co is a multinational pharmaceutical company.

**Return Rate Comparison**

* Cumulative return of review stock (LLY): 279.19%
* Cumulative return of comparison stock (S&P 500, VOO): 92.89%
* Divergence (max: 233.30, min: -31.10, current: 186.60): 186.60
* Relative divergence: 82.30%

Analysis: The review stock has shown significantly higher returns compared to the comparison stock.

**Alpha, Beta Analysis**

| Year | CAGR | MDD | Alpha | Beta | Cap(B) |
|-----|------|------|-------|------|-------|
| 2016-2018 | 37.0% | 14.3% | 33.0% | 0.7 | 103.7B |
| 2017-2019 | 36.0% | 14.7% | 19.0% | 0.7 | 117.8B |
| 2018-2020 | 30.0% | 20.9% | 10.0% | 0.7 | 151.4B |
| 2019-2021 | 49.0% | 20.9% | 5.0% | 0.7 | 247.6B |
| 2020-2022 | 59.0% | 20.9% | 60.0% | 0.7 | 328.0B |
| 2021-2023 | 116.0% | 18.0% | 115.0% | 0.5 | 522.6B |
| 2022-2024 | 123.0% | 27.0% | 104.0% | 0.6 | 692.1B |
| 2023-2025 | 183.0% | 29.9% | 121.0% | 0.7 | 963.4B |

Analysis: The company has shown consistently high growth rates, with an average CAGR of 64.3% over the past few years.

**Recent Stock Price Fluctuations**

* Close: $1,073.29
* Last-market change: -0.36
* 5-day SMA: $1,076.05
* 20-day SMA: $1,071.73
* 60-day SMA: $1,001.35

Analysis: The stock has shown a minor decline in the past day. The 5-day and 20-day moving averages are above the current price, indicating a minor downtrend.

**RSI, PPO Index Indicators**

* Market Risk Indicator (MRI): 0.70
* RSI: 50.43
* PPO: -0.33
* Recent relative divergence change: 1.50 (+)
* 7-day Rank change: -2 (-)
* 7-day Dynamic Expected Return change: 2.40 (+)

Analysis: The stock is currently in a neutral zone, with a moderate risk level. The recent improvements in relative divergence and expected return are positive signs.

**Expected Return**

* Expected Return (%): 49.70%

Analysis: The stock is expected to return 49.70% in the long-term (more than 2 years) from this point.

**Recent News & Significant Events**

* [2026-01-14] Is It Time to Dump Your Shares of Eli Lilly? - The Motley Fool (news.google.com)
* [2026-01-14] Eli Lilly: Sell It And Buy Novo Nordisk Instead (NYSE:LLY) - Seeking Alpha (news.google.com)
* [2026-01-14] BMO Capital Markets Pounds the Table on Eli Lilly Stock (LLY) - TipRanks (news.google.com)
* [2026-01-14] Eli Lilly and Company $LLY Stock Holdings Boosted by S Bank Fund Management Ltd - MarketBeat (news.google.com)
* [2026-01-07] Eli Lilly (LLY) Stock Is Up, What You Need To Know - Yahoo Finance (news.google.com)
* [2026-01-14] How Eli Lillyâ€™s US$1 Billion NVIDIA AI Lab Could Reshape Growth, Margins and Pipeline (LLY) - simplywall.st (news.google.com)

Analysis: The recent news suggests that the stock may be overvalued and that investors may consider alternative options.

**Analyst Opinions**

* Analyst Consensus:
	+ Key: Buy
	+ Mean (1=StrongBuy~5=Sell): 1.70 (~Buy)
	+ Opinions: 27
	+ Target Price (avg/high/low): 1116.33 / 1500.00 / 770.00

Analysis: The analyst consensus is buy, with an average target price of 1116.33.

**Recent Earnings Analysis**

| Date | EPS | Revenue |
|-----|----|---------|
| 2025-10-30 | 6.22 | $17.60B |
| 2025-08-07 | 6.3 | $15.56B |
| 2025-05-01 | 3.07 | $12.73B |
| 2024-10-30 | 1.08 | $11.44B |
| 2025-10-30 | 1.08 | $11.44B |

Analysis: The company has shown high earnings and revenue growth over the past few quarters.

**Financial Information**

### Revenue and Profitability

| Quarter | Revenue | Profit Margin |
|---------|----------|---------------|
| 2025-09-30 | $17.60B | 82.91% |
| 2025-06-30 | $15.56B | 84.27% |
| 2025-03-31 | $12.73B | 82.53% |
| 2024-12-31 | $13.53B | 82.24% |
| 2024-09-30 | $11.44B | 81.02% |

Analysis: The company has shown consistently high profit margins over the past year.

### Capital and Profitability

| Quarter | Equity | ROE |
|---------|---------|-----|
| 2025-09-30 | $23.79B | 23.46% |
| 2025-06-30 | $18.27B | 30.98% |
| 2025-03-31 | $15.76B | 17.50% |
| 2024-12-31 | $14.19B | 31.07% |
| 2024-09-30 | $14.24B | 6.81% |

Analysis: The company has shown increasing equity and ROE over the past year.

**Comprehensive Analysis (Summary of previous items)**

The company has shown high growth rates, with an average CAGR of 64.3% over the past few years. The stock has shown a minor decline in the past day, but the 5-day and 20-day moving averages are above the current price. The recent improvements in relative divergence and expected return are positive signs. However, the recent news suggests that the stock may be overvalued and that investors may consider alternative options. The analyst consensus is buy, with an average target price of 1116.33.

**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.